Who are Acalabrutinib (ACP-196)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): (G) BQ-L14, R-miniCHOP + Acalabrutinib, Ibrutinib combined with As2O3, V0034CR01B, Orelabrutinib + R-CHOP, FFI-1010.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acalabrutinib-acp-196.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Acalabrutinib (ACP-196) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acalabrutinib (ACP-196) (Acalabrutinib (ACP-196)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BTK inhibitor. Area: Oncology.

phase 3 BTK inhibitor BTK (Bruton's tyrosine kinase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Acalabrutinib (ACP-196) (Acalabrutinib (ACP-196)) — Acerta Pharma BV. Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Acalabrutinib (ACP-196) TARGET	Acalabrutinib (ACP-196)	Acerta Pharma BV	phase 3	BTK inhibitor	BTK (Bruton's tyrosine kinase)
(G) BQ-L14	(G) BQ-L14	National Taiwan University Hospital	marketed	BTK inhibitor	BTK
R-miniCHOP + Acalabrutinib	R-miniCHOP + Acalabrutinib	Universität des Saarlandes	phase 3	Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor	CD20 (rituximab component); Bruton tyrosine kinase / BTK (acalabrutinib component)
Ibrutinib combined with As2O3	Ibrutinib combined with As2O3	Peking University People's Hospital	phase 3	BTK inhibitor combined with arsenic compound	BTK (Bruton's tyrosine kinase); As2O3 has multiple targets including PML-RARA fusion protein and mitochondrial pathways
V0034CR01B	V0034CR01B	Pierre Fabre Medicament	phase 3	BTK inhibitor	BTK
Orelabrutinib + R-CHOP	Orelabrutinib + R-CHOP	Beijing InnoCare Pharma Tech Co., Ltd.	phase 3	BTK inhibitor, chemotherapy regimen	Bruton's tyrosine kinase (BTK)
FFI-1010	FFI-1010	Fuji Yakuhin Co., Ltd.	phase 3	BTK inhibitor	BTK

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BTK inhibitor class)

Acerta Pharma BV · 4 drugs in this class
AstraZeneca · 4 drugs in this class
AbbVie · 2 drugs in this class
Eli Lilly and Company · 1 drug in this class
Fuji Yakuhin Co., Ltd. · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acalabrutinib (ACP-196) — Competitive Intelligence Brief. https://druglandscape.com/ci/acalabrutinib-acp-196. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab